Ostarine, also known as MK-2866 or enobosarm, is a selective androgen receptor modulator developed to investigate tissue-selective anabolic activity. It has progressed considerably further in human research than many other SARMs.

Product Information

Enobosarm selectively activates androgen receptors and has been investigated in clinical trials involving muscle wasting, lean body mass, and physical function. The liquid format does not alter the pharmacology of the active compound. Ostarine is also known as enobosarm, MK-2866, GTx-024, and S-22.

How It Works

Ostarine binds androgen receptors and activates anabolic signaling in tissues such as skeletal muscle and bone. Its development focused on producing anabolic effects while limiting some androgenic activity associated with traditional anabolic steroids.

POTENTIAL BENEFITS

1. Lean-Mass Research

Controlled clinical trials have demonstrated increases in lean body mass with enobosarm, making Ostarine one of the most extensively studied SARMs in this area.

2. Muscle-Wasting Research

Clinical research has investigated enobosarm in conditions associated with muscle loss, including cancer-related wasting, providing useful data on anabolic effects.

3. Physical-Function Research

Studies have examined whether increases in lean body mass translate into measurable improvements in physical performance and function.

4. Selective Anabolic Research

Ostarine is an important research model for understanding whether androgen-receptor activation can be directed toward muscle and bone while reducing unwanted effects in other androgen-sensitive tissues.

Dosage

Clinical trials have evaluated 1 mg and 3 mg once daily in cancer-related muscle wasting, while a separate phase II study in older adults evaluated 3 mg/day. These are clinical-trial exposures, not a general recommendation for unsupervised use.

Side Effects

Potential concerns include suppression of endogenous hormone production, lipid changes, liver effects, and other androgen-related adverse effects. Long-term safety outside controlled clinical research remains incompletely established.

References

1. Dalton et al. — GTx-024 (enobosarm) in healthy elderly men and postmenopausal women. PMID: 22031847
2. Dobs et al. — Enobosarm in patients with cancer-related muscle wasting. PMID: 23499390
3. PubMed — Enobosarm/Ostarine clinical research

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

Ligandrol (LGD-4033) is a potent selective androgen receptor modulator with human clinical research examining its effects on lean body mass, hormone levels, lipid parameters, and pharmacokinetics.

Product Information

LGD-4033 is a nonsteroidal SARM that binds androgen receptors with high affinity. The liquid format is a formulation characteristic; the active compound remains LGD-4033. Also known as Ligandrol or LGD, LGD-4033 is one of the better-characterized SARMs in human clinical research.

How It Works

LGD-4033 activates androgen receptors in a tissue-selective manner. Human research has shown that this can increase lean body mass while simultaneously producing measurable endocrine and lipid changes.

POTENTIAL BENEFITS

1. Lean Body Mass Research

Clinical research has shown dose-dependent increases in lean body mass during short-term administration, making LGD-4033 particularly relevant to anabolic research.

2. Selective Androgen Signaling

Ligandrol allows researchers to study androgen-receptor activation without using conventional anabolic steroids, providing a distinct model of selective receptor pharmacology.

3. Muscle Research

Changes in lean mass and muscle-related parameters have been examined in controlled human research, supporting continued investigation of LGD-4033 in muscle biology.

4. Pharmacology Research

Its relatively long half-life and dose-dependent accumulation make LGD-4033 useful for investigating repeated exposure, pharmacokinetics, and endocrine adaptation.

Dosage

The best-characterized human study used 0.1, 0.3, or 1.0 mg daily for 21 days. Because these doses were evaluated under controlled clinical conditions and produced measurable hormonal and lipid effects, they should not be interpreted as a safe self-use protocol.

Side Effects

Potential concerns include suppression of testosterone and SHBG, reductions in HDL cholesterol, and liver injury. A published case report documented severe drug-induced liver injury following non-medical LGD-4033 use.

References

1. Basaria et al. — LGD-4033 safety, pharmacokinetics, and effects in healthy young men. PMID: 22459616
2. Ligandrol (LGD-4033)-Induced Liver Injury. PMID: 32637435
3. PubMed — LGD-4033 pharmacology and clinical research

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

• This liquid is offered as 58mg per ml/ 30ml/ 1740mg (16mg LGD 4033, 32mg RAD 140, and 10mg YK-11)

LGD-4033, RAD-140, and YK-11 are selective androgen receptor modulators (SARMs) currently under investigation for their potential effects on physiology, force-generation capacity, and somatic tissue distribution in experimental models. These chemicals are combined in a single capsule, forming a SARMs combined formula which BehemothLabz sells for research purposes only.

While some studies have been conducted on these individual SARMs, there is currently limited research on the effects of combining them.

Ligandrol (LGD-4033) – Product Information

LGD-4033 is a selective androgen receptor modulator (SARM) that has been studied in preclinical and clinical research for its potential to interact with androgen receptors. 

• CAS Number is stated as 1165910-22-4
• Molar Mass is 338.253 g·mol−1
• It has a Chemical Formula of C14H12F6N2O.
• IUPAC Name is 4-[(2R)-2-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]pyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile
• Also known by Synonyms as VK5211; LGD-4033

RAD 140 (Testolone) – Product Information

RAD-140 is a selective androgen receptor modulator (SARM) that has been investigated for its potential to activate anabolic signaling pathways associated with skeletal muscle tissue in experimental models.

The experimental chemical works by binding to androgen receptors, which can help stimulate muscle cells.

• CAS Number is stated as 1182367-47-0
• Molar Mass is 393.83 g·mol−1
• It has a Chemical Formula of C20H16ClN5.O2.
• IUPAC Name is 2-chloro-4-{[(1R,2S)-1-[5-(4-cyanophenyl)-1,3,4-oxadiazol-2-yl]-2-hydroxypropyl]amino}-3-methylbenzonitrile

Myostine (YK-11) – Product Information

YK-11 is a selective androgen receptor modulator (SARM) currently under investigation for its potential effects on physiology and muscle protein regulation in experimental models.

It is believed to act by binding to androgen receptors, potentially influencing endogenous androgenic signaling and pathways related to muscle tissue development and lipid metabolism.

Additionally, YK-11 has been studied for its possible role in supporting bone matrix integrity and modulating age-associated musculoskeletal changes in non-clinical research settings.

• CAS Number is stated as 1370003-76-1
• Molar Mass is 430.541 g·mol−1
• It has a Chemical Formula of C25H34O6
• IUPAC Name is Methyl (2E)-2-[(8R,9S,10R,13S,14S,17S)-2′-methoxy-2′,13-dimethyl-3-oxospiro[1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-17,5′-1,3-dioxolane]-4′-ylidene]acetate
• Also known by Synonyms as YK11; (17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester.

Disclaimer: The use of SARMs for performance enhancement or bodybuilding is not approved by regulatory agencies and may pose serious health risks. The benefits and risks of SARMs should be carefully weighed before use.

This information is provided solely for educational purposes and should not be construed as medical advice.

BehemothLabz Disclaimer

Please make sure you go through the Terms and Conditions, and please familiarise yourself with it as it is important. Please research the scientific uses of this product before making any purchases. Make note that the packaging and labels of the product may differ from those shown on the website.
You are welcome to review our Terms and Conditions. If you have questions about a listed product, reach us at support@behemothlabz.com.ATTENTION: All BehemothLabz products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not to be used for any human or veterinary purposes.

Andarine, commonly known as S-4, is a selective androgen receptor modulator (SARM) developed to investigate tissue-selective androgen signaling. It has been studied primarily in preclinical research involving muscle, bone, and androgen-receptor pathways.

Product Information

Andarine selectively interacts with androgen receptors and was developed as a potential tissue-selective anabolic agent. The liquid format describes the product formulation and does not change the underlying pharmacology of S-4. Andarine is also known as S-4 or GTx-007 and is commonly classified as a selective androgen receptor modulator (SARM).

How It Works

Andarine binds to androgen receptors and activates androgen-responsive signaling. Its selective activity was designed to produce anabolic effects in tissues such as muscle and bone while reducing activity in some androgen-sensitive tissues.

POTENTIAL BENEFITS

1. Androgen-Receptor Research

S-4 provides a useful research model for studying selective activation of androgen receptors and the downstream biological effects of receptor stimulation.

2. Muscle Biology Research

Preclinical SARM research has investigated Andarine in relation to anabolic signaling and skeletal-muscle development, making it relevant to muscle-growth research.

3. Bone Research

Androgen-receptor signaling plays an important role in bone biology. Andarine has therefore been investigated as a potential model for selective anabolic effects on bone tissue.

4. Selective Anabolic Signaling

The development of S-4 was based on the concept of separating desirable androgen-receptor activity from some unwanted androgenic effects, making tissue selectivity an important research focus.

Dosage

There is no established human therapeutic dosage for Andarine S-4. Human clinical efficacy data are insufficient to establish a validated dosing protocol. Published S-4 research is predominantly preclinical and analytical.

Side Effects

Potential SARM-related concerns include testosterone suppression, changes in lipids, liver effects, and other endocrine changes. Andarine has also been associated with visual disturbances in reports surrounding non-medical use, making safety a significant consideration.

References

1. PubMed — Andarine S-4 metabolite characterization
2. PubMed — S-4 androgen-receptor research
3. PubMed — SARM analytical detection, including Andarine

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

AC-262,356 (also called AC-262536 or Accadrine) is a non-steroidal selective androgen receptor modulator (SARM) supplied as a research-grade liquid solution. It is studied in vitro and in preclinical models for its partial agonist activity at the androgen receptor (AR). It is sold strictly for laboratory and research use.

Disclaimer: AC-262,356 is a research compound not approved by the U.S. Food and Drug Administration (FDA) for human or veterinary use. It is not intended to diagnose, treat, cure, or prevent any disease. This product is strictly for laboratory research purposes only.

AC-262,356 Research Background

AC-262,356 was first characterized by researchers at ACADIA Pharmaceuticals and described in a 2007 pharmacology study as a potent, tissue-selective AR ligand identified through a functional cell-based screening assay. The compound sits within the broader nonsteroidal SARM class alongside comparator molecules such as enobosarm (Ostarine), RAD140, and LGD-3303, which emerged from parallel efforts to separate androgenic and anabolic signaling in AR-targeted research, an area also explored in a 2005 Endocrinology study on SARM effects in orchidectomized rats.

How Does AC-262,356 Work? Mechanism of Action

AC-262,356 is thought to dock at the ligand-binding pocket of the androgen receptor, inducing a conformational change in the receptor's helix-12 region that allows nuclear translocation and DNA binding at androgen response elements (AREs). In binding assays, the compound has been characterized as a high-affinity AR ligand with partial agonist behavior at the receptor's transactivation domain, distinguishing it from full agonists such as testosterone or DHT. This partial, tissue-influenced activation profile is why AC-262,356 is used in research models comparing full versus partial transcriptional responses across different AR-expressing cell types.

Downstream, receptor activation by AC-262,356 has been associated in experimental models with:

• Altered gene expression profiles at androgen-responsive loci
• Modulation of protein synthesis pathways in muscle-derived cell models
• Changes in intracellular signaling cascades linked to AR transactivation

Findings on tissue selectivity are not consistent across all model systems, and the degree of AR-subtype or coregulator-dependent selectivity remains an open question in the literature.

Key Research Areas for AC-262,356

Physical, Structural & Handling Properties

• Molecular formula: C₁₈H₁₈N₂O
• Molecular weight: 278.35 g/mol
• CAS number: 870888-46-3
• IUPAC name: 4-[(1R,5S)-3-hydroxy-8-azabicyclo[3.2.1]octan-8-yl]naphthalene-1-carbonitrile
• Synonyms: AC-262536, AC 262, AC262, Accadrine
• Form supplied: research-grade liquid solution in a stabilizing solvent carrier, formulated for solubility, stability, and ease of volumetric measurement in laboratory settings
• Physical description: the parent compound is a naphthalenecarbonitrile-based small molecule; the liquid carrier is selected to keep the compound in solution across standard laboratory storage conditions

What Are the Risks and Limitations of AC-262,356 Research?

This section is mandatory reading before working with AC-262,356 in any laboratory setting.

• Handling Precautions: AC-262,356 should be handled by trained laboratory personnel only, in a controlled research environment. Use appropriate PPE at all times. Avoid direct skin contact or inhalation of any aliquoted solution.
• Exposure Risks: AC-262,356 is a nonsteroidal SARM thought to interact with androgen receptor signaling in preclinical models. No human safety data exist for this compound.
• Storage: Store AC-262,356 Liquid at −20 °C in a dry, dark environment, protected from light, heat, and moisture. Avoid repeated freeze-thaw cycles.
• Toxicity and Data Limitations: No chronic toxicity data exist for AC-262,356. All available findings come from short-duration preclinical and in vitro models only, and results are not consistent across all systems studied.

AC-262,356 Liquid: Frequently Asked Questions

What is AC-262,356 classified as?

AC-262,356 is classified as a non-steroidal selective androgen receptor modulator (SARM), distinct in scaffold from steroidal androgens like testosterone.

How does AC-262,356 differ from a full AR agonist like testosterone?

It is characterized in laboratory assays as a partial AR agonist, producing a smaller transcriptional response than a full agonist under the same experimental conditions.

How does AC-262,356 compare to other research SARMs like RAD140 or enobosarm?

All three are nonsteroidal AR ligands studied for tissue-selective signaling, but they differ in chemical scaffold and in their reported receptor-binding and selectivity profiles across preclinical models.

Is AC-262,356 approved for human or veterinary use?

No. It is not approved by the FDA for human or veterinary use and is sold strictly for laboratory research.

How should AC-262,356 Liquid be stored?

It should be stored at −20 °C, protected from light, heat, and moisture, and handled only by trained laboratory personnel.

What to Look for in a Supplier When Sourcing Research-Grade AC-262,356 Liquid?

Check that every batch is independently third-party tested for purity and identity, and that a Certificate of Analysis (COA) is available for each lot. Prefer suppliers that sell strictly for preclinical and in-vitro research use. You can consider verified suppliers such as Behemoth Labz, where compounds are tested through an independent laboratory and sold strictly for laboratory and research use.

Note: All products referenced are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not to be used for any human or veterinary purposes.

Disclosure: This content is for informational purposes only and does not constitute an endorsement of any product for human use.

References

1. Piu, F., Gardell, L. R., Son, T., Schlienger, N., Lund, B. W., Schiffer, H. H., Vanover, K. E., Davis, R. E., Olsson, R., & Bradley, S. R. (2007). Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator. Journal of Steroid Biochemistry and Molecular Biology, 109(1–2), 129–137. https://pubmed.ncbi.nlm.nih.gov/18164613/
2. Gao, W., Reiser, P. J., Coss, C. C., Phelps, M. A., Kearbey, J. D., Miller, D. D., & Dalton, J. T. (2005). Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology, 146(11), 4887–4897. https://academic.oup.com/endo/article-abstract/146/11/4887/2500134

ATTENTION: This content is for LABORATORY AND RESEARCH PURPOSES ONLY. Not for human or veterinary use. Educational purpose only. No human consumption.

Cardarine, also known as GW-501516, is a PPAR-delta agonist that has become particularly popular for its association with fat metabolism, endurance, and energy utilization. Unlike SARMs, Cardarine does not work through the androgen receptor.

Product Information

GW-501516 was originally investigated as a PPAR-delta agonist for metabolic conditions. Research has shown that activating PPAR-delta can influence fatty-acid oxidation, lipid metabolism, and skeletal-muscle energy pathways.

How It Works

Cardarine activates PPAR-delta, a receptor involved in regulating how the body uses fats and carbohydrates for energy. This can increase pathways associated with fatty-acid oxidation and alter fuel utilization in skeletal muscle and other tissues.

Potential Benefits

1. Supports Fat Oxidation

Cardarine has been extensively studied for its ability to increase pathways involved in fatty-acid utilization.

2. Endurance Research

Its effects on skeletal-muscle energy metabolism have made Cardarine particularly popular in endurance-related research.

3. Supports Lipid Metabolism

Human research has demonstrated changes in triglycerides, LDL-related measures, and other lipid parameters following GW-501516 administration.

4. Supports Energy Utilization

PPAR-delta activation can shift skeletal-muscle metabolism toward greater reliance on fatty acids as an energy source.

5. Metabolic Research

Cardarine has also been studied in connection with insulin resistance, liver fat, and broader metabolic pathways.

Dosage

There is no approved therapeutic dosage for Cardarine. Published human studies have examined doses including 2.5–10 mg/day, while a forensic review notes that 10–20 mg/day has been reported in performance-enhancement use. These figures represent research or reported use rather than an established safe dosing protocol.

Side Effects

The long-term safety profile of Cardarine remains a major concern. Research has raised concerns surrounding tumor development, while other potential issues include changes in metabolic markers and unknown long-term effects.

References

Dressel U, Allen TL, Pippal JB, Rohde PR, Lau P, Muscat GEO. The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Molecular Endocrinology. 2003;17(12):2477-2493. PMID: 14525954. PubMed

Ooi EMM, Watts GF, Sprecher DL, Chan DC, Barrett PHR. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity. Journal of Clinical Endocrinology & Metabolism. 2011;96(10):E1568-E1576. PMID: 21816786. PubMed